Home | Business News | CBJ Newsmakers | Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors RecommendedMedallion Resources Announces Private Placement of Up to CDN$2,000,000 and Debt Settlement of US$650,000Jade Power Announces First Escrow Release and CVR DistributionĀ and Filing of Q1 2023 Interim Financial StatementsFLINT to pay interest on Senior Secured Debentures in kind
